- Earnings call transcript Q3 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to CureVac Third Quarter and First Nine Months 2022 Financial Results and Business Update. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions].

As a reminder, this conference is being recorded. pleasure Communications your and my Vice Sarah now Corporate President Investor is to host, introduce Fakih, It Relations. Thank you.

You may begin.

Sarah Fakih

morning, name and me introduce Thank conference Investor Relations of Good good speakers. Please welcome and and you. let CureVac. to Corporate call. Communications My the is I'm Fakih, today's at Sarah Vice President afternoon our

Officer Chief Science Chief this & on On Kemula, & on will Please Senior Officer; call Relations Ulrike Executive the the is Haas, of Chief our Pierre site. Events with call and Plasterk, our Innovation; me Development Financial Interim CureVac. Franz-Werner Vice be note being Presentations the and Investor Ronald Web that from President section under webcast CureVac are live Officer; our archived Gnad-Vogt,

statements. a Wednesday, discussions questions view begin, to your reflect forward-looking this today, as of we responses few on XXXX. and call management's XX, The November Before

providing our These or your making projected. Harbor We to could revise those questions involve responses provisions. be statements These forward-looking any to constitute of disclaims or to state that of intention predictions uncertainties results materially the statements differ for statements the will cause that and CureVac purpose from forward-looking Safe expectations beliefs, the any and risks obligation intentions, actual future. statements.

please call to Franz. over with information, the I the turn U.S. refer filings more to our Commission. For now Securities and will Exchange

Franz-Werner Haas

from conference highly Thank here a productive you, this our welcome CureVac. call for company. us Sarah. XXXX Ladies gentlemen, been year and at to has a warm

GMP competencies; bandwidth development robust pro importantly significantly and three our pipeline manufacturing core most product operational have organization platform, the capacities. grown We and large across technology our

areas. overview you key of give developments in a these four Let short me

to continue started product in broad XXXX with successfully multivalent collaboration First, that data pipeline, deliver trials on which in GSK. approaches are programs in clinical four to our our in our earlier COVID-XX technology and year. track flu, as well vaccine have on mRNA into early modified next execute prophylactic development extended partner as broad ongoing clinical we meaningful our The platform clinical

in driver beyond and growth next progress focus are our forward Second, maximum prophylactic moving the speed is oncology. with vaccines, we

of Immuno-oncology acquisition have Cancer out cancer gap. that oncology data to individual gap Therapeutics is methods partnership of about meaningful data an start of an options. implementation translate particularly the strategy. current cancer hub. we plan of treatment to with made make between driven available our expanded Amsterdam, impressive state-of-the-art We a is myNEO, access which antigen former patient's discovery vaccine our that Today, into the amounts With and candidates provide Frame there Therapeutics Frame the mRNA to we the bridge new cancer of and suited and enormous in vast Cancer analytical to intend pipeline site

patients advanced Society the we at the are of CVXXXX advancing vaccine enablers, dedicated to or Third, earlier Cancer, applications preliminary CVXXXX also of licenses technology, the for mRNA The on Furthermore, SITC, RNA we therapeutics. oncology oncology the submitted for foremost, demonstrated the the for vaccines we oncology progressed expansion Printer, efficacy delivery pretreated this manufacturing solution cancer lipid we of first of roadmap. RNA first proprietary our candidates. provide non-coding of the safety and In GMP-grade Phase development additional this and our our with support authorities nanoparticle, heavily Fourth, manufacturing data mRNA for month. Immunotherapy melanoma. year, of to in that novel solid October presented expect regulatory we study a the to from meeting in development and profile advantages the automated X LNP

briefly talk our of unmet prophylactic €XXX.X you closed with with therapeutic strong across mRNA highlight through we expertise therapy, X, how a will leveraging addition financial later you On solid the addressing medical our of we need. of quarter to And third diseases pipeline In developments, vaccines, position areas the details. to high four cash show oncology let XXXX three are Pierre CureVac Slide the those me and million. molecular

develop in our COVID-XX are these Our area, formats these technological multivalent monovalent second-generation studies is four This together The currently insights being the will responses area, strong clinical that can well priority four by vaccine of expansion as portfolio as diversify we technologies, accelerate prophylactic clinical product strategic and X versatile advance of candidates validated new implementation based and approaches the product ongoing advances differentiated are oncology development allow candidates this All synergistic tumor featuring to engine. our broadly mRNA second-generation of efficient conducting most that and of our with on advanced discovery driven expect antigens gain well pipeline. our development backbone. our elicit immune GSK. in established vaccines, cancer as associated is backbone mRNA unmodified In as antigens. Through also we a systemic This Phase spends will backbone. and novel and the a the modified directed from to flu we vaccine of to trials antigen us tumor program. high

conducting rare for select are therapeutic the and let in a overview of address COVID-XX a together on X detailed treat refractory briefly with we will expansion area, to X, on highlighted, are a currently touch partners currently with development. broad several On trial study that Phase our oncology X mRNA the an in with to is Ulrike patients four studies the dose escalation are being solid escalation assessed tumors in performing key The and back Phase come trials stage that optimized already diseases. by to intended me are clinical melanoma. PD-X together In and GSK. we CVXXXX technology clinical data candidates later developing at in Slide best approach As flu dose CVXXXX molecular driven the therapy, proteins collaboration therapeutics therapeutic to third presented SITC. we candidates metabolic

virus. unmodified For candidate COVID-XX, the CVXXXX, the candidate encoding modified the on an a and the left, includes original Omicron encoding candidate CVXCoV, tested variant

For allow technology that optimal of our for the and trial. enough be reporting triggered flu, SV four and of dose important one and Based All FLU platform on promising modified CVSQIV, setup. subsequent our are a second-generation candidate. candidate in backbone, development. indications selection meaningfully clinical mRNA, right, shot an we are determine validation by booster clinical and Initial will external product candidate advanced being the corresponding monovalent will a to an on are a most candidates data for unmodified tested testing both quadrivalent provide they the comprehensive

to XXXX. this early in We on report data expect

Moving this to on walk updates will you Ulrike vaccines through now progress in to from I prophylactic recent and area. oncology, hand our over to

Ulrike Gnad-Vogt

Franz. you, Thank

Before I like These roadmap pillars briefly oncology illustrate our we prophylactic footprint, expanding vaccines. progress oncology. are would the attention dive the details, your our to next to in our we strategy in growth beyond draw for previously advancing driver the three-pillar into reported rapidly

antigens months, to differentiated Therapeutics technologies those early Over RNA either with strategic pillars and identify pillars the on have solution engine to clinical myNEO enable chance the a several discovery us on assess of to right. pipeline. started The of The the studies. in stage middle new This clear development will vaccine constructs vaccine trial execute continued or with material mRNA of tumor and in Frame success antigen The and supported each the on the focus rapidly cancer Cancer we classes for of automated last expected of to a will highest novel the to of potential with alignment by end-to-end clinical be contribute availability is the Printer. testing in screen manufacturing these clinical

first The cell-mediated to our to support presentation. our are of RNA second-generation strategic responses discovery already the on different antigens second-generation back by the regulatory in in strategic This will the in review includes manufacturing for this I by T As licenses testing initial pillar left. mentioned validation come Printer classes Franz, currently later pillar tumor the backbone oncology. and obtain to immune validation we backbone with to the assess of

in technologies oncology. a deep developed look how technology closer provide that latest technologies how product Therapeutics expertise the integrate competencies our our our with and Frame novel bioinformatics development antigen see oncology at and complement in of candidates Cancer an myNEO pipeline establishing along to to reach They are manufacturing. technologies currently expertise. advanced a the can in being illustration First, discovery deliver and our Slide then you strongly can The extend core our take cancer while with let competencies of be On we compatible mRNA into technology. highly existing synergistic powerful of us vaccine they core the own three antigens a frontend and X,

Cancer Frame hand now of technology. the sophisticated to Frame's you the Therapeutics, the walk differentiated call of over details through highly me to Founder and Ronald, Let

Ronald Plasterk

with you, earlier acquisition has is harnessing of The of become the this to which treatment by platform part system recognize transforming year the Ulrike. and cancer dedicated the Thank technology immune tumors. fight to CureVac the technology

expressed we the whole with way, of every only every and serve mutations targets patient apart all full of technologies overview candidates. can tumor The the resides. sample the software It or capacity what data genetic for the years, and healthy integrate know precisely sequence sequencing. been Over start found of what parts the cells, perform where genome prices engine. in an genomic This the of This progression industry antigenicity long-read antigen package for is tumor the to information. breakthrough map give which larger technology changes tumor developments as antigens inventory as data we combine going our correlation that remaining exact are enabled sequencing changes exome, the the retrieve three patient XX.X% where us RNA of generated of the sets you well We compared a next discovery to new X.X% we short the the field would and sequencing genome being still efficient as new human these to go information the short genetic the like on from $X,XXX, the in can the antigens of with to frames, specialized targets changes and is genome. enables it further genetic recently, powerful Downstream cells that has provides not. was can identification extract entirely and of the bulk current our cancer and and potentially we of to all patient the cells is sequencing, this our transcription advanced be RNA of platforms vaccine entire portfolio such Today, proteins. only demonstrated with coding Within as frames I of frame generation Slide can to plan of vastly of extraction have tumor of two data. total the in point down. of the within give We've rise sequencing. data and of as of for the the tumor the amounts indeed XX from XX what in next reading new and focus immunotherapy We've open this design to vaccine to. represents mostly We slides, cancer called is entirely for approach from available protein antigenic in to about this vaccine More neo it sample tumor weeks. cells which last to tumor standards. data that candidates. can these utilize of for to In the antigens. I'm results X.X%, new is depth on samples now on that of has But access the illustrate the apply we DNA

show chromosome of cancer the data the work. dots The see own tumor our vaccine dot chromosomes. Y obtained potential can and DNA. patient circles dots. of blue blue depicted figures you as Each the illustrates is a circles whole middle represents only we left illustrates data The The by the from Here both The per genome The both do parts a only coding lung chromosomes number figures the of figure plus sequencing. real figure number inner of cancer the the a analysis XX outer in restricted blue X exome protein sample obtained if to the we target. of sequencing. sequencing from of conventional we mutations choose

middle you point more lines of more The gain that. Here, get figure, but importantly which the the where more chromosomes are of many much rearrangements chromosomal point of is multitude in should on chromosomes case data course, they you not top the meaningful in tied be. other to of where mutants, depict

to for be single hundreds encoding entirely means entirely main rearrangements max represent the results cancer also point potent the different sample. or in point course in that against mean vaccines? of both new difference the a are tumor Framome. body. This about around between acids. rise most changes, of only in ability staggering. Overall, based uniquely there antigens system of development changes While stretches that common wild-type number Recall the rearrangements vaccine taking such protein the of incorporating cover are mostly Well, healthy rearrangements the common In limited. to expressed at cancer the does genetic a wild-type then in amino that a in of mutations, immune but to Current part to datasets the antigen the the not cancer, vaccine. entirety based genetic this lung is of is occurrence The regular genetic that This these can difference not activate for only consequently so we is the amino is still contrast, in this a as What in the vaccines name all the single tissue. XX give frames, content. cancer content features personalized changed totality XX approach the healthy the very mutation, implies, vaccination a on the nucleotide DNA, such or is of and are new approach, applying of acids expressed including long derived on this the body, foreign foreign and the

the this here on new types. the showing separate the encoded believe The does system add sample represents lung and acids immune let is the we or is an expected, protein will a between how in construct. that on this are Every fight color game. we game. amino our the can that approach obtain extended the here of even like Slide strongly in of RNA encoded you You as the our every a number provides look In about to on tumor also focused the cancer that acid. approximately or individual construct patients. -- of on virus that's right. different with shared by of patient can lung now can the even branches are here the patients. day, with found same approach across some and Framome numbers far cancer suggested the immune immune single see messenger line that the show data leverage number today opportunity win can much XX we X,XXX two same experiments, across can me foreignness, What sample. frames that new line cancer different At up that to a colors small best different Having see the end between samples, And you And so response. from tumor frames cancer of We a be to a to amino raise easily a preclinical a its system stronger the

tumor develop frames shared In many us of approaches a our And we different vaccine well following in be shared as vaccine development. patients. could two are why for candidates antigens the associated fact, cancer types. larger That's to that potential applicable occur offer they cancer cancer group to as

vaccines cancer approaches current discuss Ulrike? of is Ulrike patients of tumor approach tumor individual within assesses a cancer oncology The hand the by to shared first the off-the-shelf second to me profile. the back let to development how fit for And patients. With groups larger our these patient's different approach call to roadmap. that, antigens benefit tailored

Ulrike Gnad-Vogt

in mRNA cancer I through our XX oncology candidates. you we now how XXXX and Ronald. to for new translate walk beyond, into am on Thank to plan plans technology and our Slide development you, vaccine

the 'XX in studies a safety You might and and cells translates assess preparations antigens. our improved second-generation of To To tumor to X T first induction first into will backbone how half oncology. pillars two already second-generation backbone, of proof end, address started remember in in principle of have the a to highlights pillar, including established second-generation strategic this Phase initiate that of of we clinical three performance the we the the second backbone the of immunogenicity validation setting. of assess this the

expected first of proof study with in associated of an first half glioblastoma construct assess 'XX start mRNA principle encoding from to patients multiple The a tumor the in will surgically resected epitopes antigens multiforme.

second expected a proof to featuring subsequent initial focus full half discovery regulatory an tumor of stream clinical which processes. we tumors has of as In provide to second include The the clinical what construct on potential will validate to in with mRNA antigens parallel, the identify availability flexible are to of of from study vaccine associated the primarily additional new support accelerate expected cancer support with benefit support work start solid development and oncology advancing clinical and for candidates data These The to in rapid of which tumor length associated will review our antigen melanoma. a trial an call They principle be materials. patients antigen solid application of enablers. we foundation as This 'XX, the the Printer, testing. engine and of RNA well antigens will

development highlighted; off-the-shelf cancer two vaccines in benefit programs. to Programs to and of studies based the to successful merge patients will of has of cancer improved to profile. on vaccine and we approaches mRNA patient's based cancer candidates antigen groups for optimize proprietary cancer Additionally, tailored are vaccines vaccine work new in and streams encompass individual principle order proof design the selection development the to start delivery. tumor data from a LNP Ronald aim Both on program XXXX expected of

slide. detail go two next into approaches on more these me the about Let

of these antigens cancer for antigens, of increase high access evaluate that to of addressing, breast these relevant this will suggests with concept as four shared about shared introduced antigens, that shared tumor further negative of data a even collaboration associated With off-the-shelf frames our are third earlier the discovery match presentation, the we cancer at tumor. cancer from other populations antigens an the quarter a of and or four at of prevalence two out breast engine can coverage candidate. to chances patient's a most antigens frequently least address shared for example, antigens patients. antigen in our Looking well Due the tumor triple all our off-the-shelf to vaccine classes to as will associated out specific myNEO, specific patient with possibilities turn vaccine

Our system tumor. to XX, The to a that illustrated patients it to optimized is represents did slide X two pretreated is parts the that dose a antibodies. evaluated program, treatment. this antibodies. which it second or cohort. not the now it were dose vaccine show the a the with Slide with cohort cancer viral is objective approach path the of the are to range partial anti-PD-X were advantage of XX consisting patients can with of of injected our for a well CVXXXX can update in pretreated been the patients efficacy responses depend a comes are activate XX RNA approach. patients. non-coding personalized The other and a best In single that at group, precisely the Ultimately, directly by PD-X tumor in from these of is in a assesses for approach, August CVXXXX immune data shared Phase into assesses infection on anti-PD-X of refractory in has cutoff addressed to observed or including that data X XXX a the being part and responders individual one off-the-shelf and micrograms. tumors XX% date of viruses, mimics where tumor toll-like me combined solid anti-CTLA-X patients currently of XX% shift and briefly as RIG-X. RNA a Five expansion oncology the in heavily to that, study normally the study, melanoma X personalized you whether reject of the combination agent year durable tumor patients data research. of XX experienced me activate antigens with already CVXXXX patients will receptor with has be fully CVXXXX. latest the on the this observe about tailoring combination talk up as On With CVXXXX let of and preliminary start with as which let gears were specific responses on The or patient's from an a remind single receptors year detect the pretreated completed. and antibodies. agent anti-CTLA-X from A treated We XX% according not response antibodies. in XX these that escalation

tumor left Slide the data previously by CDX cells tumor one confirms a cohort. of a all the X is reported Additional The infiltration samples the and further the in in injected tumor CDX as the responders characterized T Phase immune in based of and on XX biopsy as profiling from and of expansion tumors subset cell study T decrease both shown combination corresponding of the content cells blood partial is from environment and non-injected the patients on on patients. of sample biopsies shown from tumor well

'XX. Overall, slide, based the before the side reported reported profile activation to peer-reviewed robust X RNA induction on X [ph] plot complete by first is right the the half study first defense of the further Phase analysis of demonstrates samples illustrates positive hours study Final safe interference. CVXXXX. Phase be the data CVXXXX of more confirms balloon after in administration the a in tumor. strategic clinically and injected focus the complementary on potentially of well our candidates immune specific to antigens, as technology. characteristics development strong to tumor a We development based further vaccine non-injected back defined call that mRNA and With context immuno-modulatory strong on the would led cancer and set example, the sequencing pathways analysis as target for gene clinical vaccine the mobilize mRNA previously me expected XX the publication integration Franz. candidate. of our as expansion CVXXXX validated from enrichment submitted cancer an into taken for therefore the only of adjunct a of journal vaccine safety CVXXXX of to consider the cancer a data previously represents development, The of of hand this, immuno-modulatory a against On let a ability valuable In of blood potential system a

Franz-Werner Haas

injection Ulrike. the on LNP. the Thank that To an Preclinical Biodistribution composition. nanoparticle, oncology highly limited the address a vaccine rabies-based or new localized was our LNP XX, of showed candidates. new of the LNP a being components for such control compartment PEG with in potential you, liver, up application organs and cancer It XX The Slide no non-PEG round spleen improved oncology or the to with LNP consists mRNA Slide distant lipid our me mice Ulrike either the in on and the let experiments new transcription free intramuscular enablers highlighted proprietary roadmap lung. immune showed as lipid and site. and a program, two XX, briefly formulated first expression of already and

T presenting a was immune correlation Correspondingly, linear encoding CDX but of in public therapeutic resulting from of antigen repetitive mRNA cancer between a an administration, the the vaccine with know fighting treatment the antigen cells. tumor expression is strong also cellular the to and amount We activated abundance important immune of compartment cell be goal. As immune studies delivery the maximizing that the highly by there in accompanied responses. humoral compartment seems the localized requires

we interferon rabies LNP antigen generated as T systemic same the amounts the non-PEG mRNA LNP vaccine. LNP cells important alpha still logistics on to the shown presentation rather mRNA comparable from was mRNA The ongoing program storage XX enable show slide, vaccine for right stability via The with storability. side was and at than powder a referring in XX As specific dried an add Fahrenheit, so-called that for An of demonstrating new vaccine mRNA competencies the a at the based pose for to formulated Slide figures control the raise the shown approaches extending degrees solution LNP a assay. our the interferon of study and to range of optimization. long-term a the distribution Overall, formulated advantage XX addresses is solid program of in gamma securely data measured levels technology that are research design formulated better the as new shown the ELISpot and core XX on cold to degrees challenges or new LNP for least weeks. chain of and centigrade stability intact

of the role XX, of pipeline, cancer avenues the to new RNA personalized on to second the but for at opening internal based The also like Slide envisaged mRNA not Moving oncology Printer oncology enabler expansion would on our in I look is to play therapies. only the in

our manufacturing sequence to vaccines setup. provide seamlessly also therapeutic treat At antigen to of of of integration fully The catalyze could Designed end-to-end Printer smaller The vaccines or same personalized know, for RNA RNA Pierre, and flexible expected the vaccine the a Printer and is workflow. provision possible This the either for this, new our a financial Printer patients data for along over of hand or me data. and Printer quantities, pipeline. you the integrates review solution therapeutics. of The GMP-grade you, personalized the With entire RNA rapid therapy off-the-shelf integrated mRNA vaccine suited scale As automated let smaller is our gap data group digitization of vaccine and cancer the The management uniquely time, our technologies and discovery development to be to the cancer of RNA between with close

Pierre Kemula

Thank Franz, afternoon to morning and the call. good you, on good everyone and

purchases to first current the for CVnCoV. months at its closed strong advanced Looking first in exposure cash generation activities position R&D the operations million. allocated wind-down transition of CVnCoV year to the the its production program reflect of XX, €XXX.X Slide mainly part of and settling phase of and a on position CureVac's months with XXXX capital of our statements Financial for CMO third nine we expenditures quarter nine cash for candidate the out of new as contracts vaccine facility. used Cash to material and of was a first

XXXX. to of the first of its for recognition first XXXX total Ingelheim XXXX year-on-year highest for to nine-month €XX.X million and amounted the ending the based decreased collaboration million €XX.X million to September to €XX.X of quarter million a statement, the was nine-month the our €XX.X by by quarter €XX loss million first decrease XXXX. to The and revenues €XX.X termination and was months loss decreased of for the compared increased in on same a our collaboration months to XXXX. XXXX two GSK third million third XXXX, nine of the due million for compared Revenues period XXXX million €X.X Boehringer period third for the year. Moving for profit €XX.X first the million previous and of compared of nine Operating quarter to on €XX.X the subsequent the of representing decrease for the to revenues

the as from to declining several million number Prior operating expenses to million million CMO. increase CVnCoV. clinical year by to nine completion reserves development materials offset XXXX in September operating remaining end trial decreased production network due the significant result large GSK months decreased the €XXX.X of of €XX.X the write For expenses total of our following contracts goods for significantly sale the the drivers. for resulting manufactured a was now ended raw be loss reversal by of the primarily the at for expected of XXXX, the decreased European key CMO due December year-over-year. Phase longer GSK. in Cost cost decreased are in continuing first for with services. to XXXX, the study CVnCoV. In first used XXXX. months recorded XX, of to capacity partially the to affected procured supply transfer estimate related XXXX by to was expenses line and primarily lower was expenses by of of The €XXX.X nine to CMO an These off highly This for in setup lower impacted XXXX R&D of no in renegotiation clinical of participants trial XX, Xb/X existing provision

for million to to quarter production from primarily by XXXX. R&D the of million income at in In setup nine change production volume quarter increased the to With positively on estimate from compared the recognized first XXXX activity gain months for the exchange €X.X and the million of was €XX.X German Franz foreign in million €XXX.X XXXX, cash GSK months were third I €X.X a Financial transfer to takeaway. results cost a key amounts positively hand of quarter by and nine of this, third impacted million quarter gains of grants of following for XXXX, €X.X million for the €XX.X the attributable and to by like investments. other at and GSK was was in of Pre-tax losses from Federal impacted Additionally, interest today's results These CMO. capacity but by Other back XXXX reserve and for Education or CMO. first net by the would financial Research, period to prepayment third income for same €X.X positive the the in Ministry for to reimbursement million were first BMBF. the XXXX. driven decreased

Franz-Werner Haas

thank and and Ulrike Pierre, also you, you, Ronald. Thank

the quickly key takeaways me from today's Let presentation. summarize

continued the across Over enabled manufacturing. capabilities development for to technology maximize the core we product applications competencies, strongly past operational and months, increase including several to three mRNA our us our that technology,

its preparations The this pipeline expertise to technology. strengthen genomics plan We COVID-XX vaccines are backbone provide on acquisition performing support our trials and this goal cutting candidates In supported platform. meaningful select our our mRNA early data track and by where of LNP with the highly prophylactic best development novel and the second-generation pipeline four versatile bioinformatics with candidates next our oncology we influenza have have GSK. cancer year advance and stage expanded potential edge integrate our year, Therapeutics developments to significantly clinical in to total program with later trials platform with in clinical in and clinical together trials expanded by new RNA Cancer two oncology differentiated in and will of start also for XXXX, XXXX. we vaccine Printer our to This a development technology data four a by subsequent clinical Frame All of development clinical

this, continue third the the priorities. like balance strong shows presentation. in work your vaccine to first positions execution cash diligent for our quarter we to resolve webcast the Lastly, our questions. And conclude our on us from and benefit our With from candidate our would now the I well prior and reallocate to commitments open generation

Operator

Thank you.

session. conduct question-and-answer [Operator now We Instructions]. will a

comes Our America. proceed. with Meacham Please of Geoff first from question Bank

Geoff Meacham

update us question. program. my you're taking market rabies curious you next And for through also Thanks on your thinking looking opportunity there? walk be we Hi. how that you. just about I'm for a should can Thank when

Franz-Werner Haas

flu regard is efforts first With to on on the infectious Geoff. will of the looking our is as the making the yet. difference were why trials GSK regard in about cannot not trials. to at clinical clinical Therefore, tell well pandemic the to over you, partner Certainly, with certainly something question your Thank all concentrated moment. disease, you certainly as the COVID a together into efforts our readout answer which which with platform core technology rabies, the on rabies the I these

well. indications the waiting the we as other be for for these then are to come this more So and will in markets us for because data indications telling certainly

Operator

Wang Our Guggenheim. next proceed. question comes from Please Evan with

Evan Wang

terms present And they to you decision the no or and how there press modified it? in that to medical would Are Great exactly for programs in question. at in on helpful. a us release meeting? flu go it a presented for of and be taking data just Thanks between COVID plan Great. go, to color Any will the together? see unmodified, Can clinical the the planned Should made? be be we expect my track remind how you for XQ.

Franz-Werner Haas

you, on data. present are this now we going to to It too say a Thank how bit Evan. early is

see to be what pointing on of to finger RNA want assured is the the the moment what we this is in first-generation have First, the One exactly with data, discussion is the at the order the readout. we're where your can the find you GSK having core But together that between backbone, backbone constructs is non-modified a whereas difference modification, second-generation really higher sense. RNA two the just on, second-generation versus potency. in backbone level the

was you're modification, see you reactogenicity, for role certainly more that. because on multivalent plays especially the then chemical you the RNA with into to RNA together the know, As higher you're dosages, CVnCoV really the with non-modified a can do going if which level, what but first-generation putting

been So according improvements these we are doing GSK how only certainly put high the to this. we then able will data, partner answer projects the about the present far. finger critical trigger expectations too these to are really Therefore, a on And when have questions have exactly of with certainly we so which which our it's to here. unfortunately, are also talk running this and are we your on our to bit you we points, going early exactly mutual we see

Evan Wang

cohorts, of And kind or stage follow flu the to XQ of the humoral cell consideration season? possible you kind start terms before of data stage what have -- development the have do of a as patients, then a follow programs of the they present response? influenza is terms of is up, kind As later will of for terms Thanks. color of in to it COVID, T any or scale next see and of to later provide of can in in dose number up, in in it expect you kind

Franz-Werner Haas

Thank you.

tried what a the explain playing the as readouts, on expectation, and start the is we versus modified technology level, that to what want this the put to well, where our is next then non-chemical into backbone role we second-generation want oncology modified chemical we trials for the to is there tried presentation So to clinical see in also certainly we as year.

especially multivalent, going the vial, in therefore, chemical South see this the non-chemical first low the more one the course, a three points. and into infectious a So as as you CVnCoV, RNAs is effort this because us disease, our put well, know. earlier same year, is with this certainly, far giving to problem a beyond versus modified certainly is it's the of as America modified, then as other exactly we is a bit the if in starting which was clinical that you there dose, trial One first started reactogenicity, technological monovalent of well which

one immunogenicity. is the The second

role as expression is for the one the well. cell neutralizing really and is also then certainly beyond third again presentation, a there infectious what So disease the plays which oncology And T various antigen titers.

and what So part it does in these COVID your flu? further in address we're main looking points last it question, development product the -- to does as are what this mean of to mean into is for well next the as

Evan Wang

Great.

back Looking Thanks. queue. to in data. forward I'll the the jump

Franz-Werner Haas

Thank you.

Operator

[Operator Instructions].

Our next Evercore. with Please question comes from Miller proceed. Jonathan

Jonathan Miller

this you And pursue typical waiting other products. COVID jurisdictions? in stage unmodified? on in guys. you was want to visibility say those unmodified you similar RNA. message GSK unmodified fair to currently anything results the is that before the to I'd Because disclosures you're on product? visibility year, lawsuits decision on Hi, to IP being back to holding like suits ongoing on to Where the a results check modified you're to into and obviously you share And by Is pushed how those it timeline what's are process getting what little German the secondarily, now? Maybe the driven with on And back seems it's the plans backbone? for lawsuits that the trials, any courts, much then bit are love do taking COVID modified on have seeing versus my the here the expected that extent that from it question. the it those Thanks like in seems have in

Franz-Werner Haas

Thank you for question. this

in when clinical always these was separately we that we to to non-chemical same On make trials chemical modified would because just indication here the communicate considered sense. that this -- versus compare we not started the it want want on separately didn't data, modified didn't

the report data of on for this We the have And structuring on program. the why that at the see, to This moment, And as the are, completion holding and non-modified. for and is product readout next also nothing been is trials we product development? certainly you well picture. then data. this the and expectations the is have this this exactly really need the that's the high do meeting to modified not is step the full started GSK development? us is to the to and therefore, when a what with is next us, because step readouts clinical both, exactly one And has these give as to the goal, for visibility okay, we back And what

this insight see which consider BioNTech. how And court the started timelines, IP look while certainly least we're here, would for has process have and BioNTech against a There we as by in, the very to file, us about here is be this the will a would Germany, the to take claims court the as then responded in talking evaluate. we handed in which public complex order which On been you into will an hearing, give no this. at can

much It that as rules to from is say now. has process. following are waiting first normal this the and just of year from process definitely can say follow the as So court going one, the the in -- for I'm the we process started. nothing with And I here, been this

Jonathan Miller

go onco fair point areas in little I vaccines, bit non-coding context? more How result detail usage the could you frequently about And guess for that's on targetable in the into antigen identification? non-coding maybe mutations then do vaccine Okay, of enough. in a a regions expressed just antigen

Franz-Werner Haas

chromosome, of lines and at for another on that could much for series from therefore -- which activating studied, other say is gets well. out as cells sequence part mice the also cells a every tumor results the from junction, also done couple that chromosome tumor X the in for in quite one and a actually a junction un-coding of side if in roughly, we've cells, samples. taken you to translatable coupled detectable that taken Thank to and become look XX very that where We've you becoming about an cell of And that numbers we of gene both cells question.

results where such it sequence. an about it's in So actually cases X XX in expressed

Jonathan Miller

rearrangements, chromosomal mutations not regions. not point this obviously in just For non-coding --

Franz-Werner Haas

because point right. right, why that reason much at in followed up non-coding no there's region haven't all. and be it would a the coding say to a That's antigenicity, contribute will that mutation I doesn't we

for So mutants expressed rearrangements my point especially in sequencing the expanding the those to XX.X% the view, lead those that to detecting to stretches. in not interesting is, non-coding stretches being and

Jonathan Miller

up follow in tumor that, the tumors often overall. how all to those And the is rearrangements rearrangements rearrangements basal often are to tumor? clonal as a that for across tumor, then relatively the those obviously how chromosomal are is in But frequent to the cells say coding

Franz-Werner Haas

available the at types but such Yes, sometimes those not that many different numbers. the public differ, rearrangements ourselves, are in frequencies indications, of looked were by in different two give questions. also We've And in interesting we're Actually looked at way. generated databases. you and to an manuscript indeed, all cancer writing a data

important glioblastoma that glioblastoma example, brain the poor mutants, chromosomal from such much relatively rearrangements. be find we very in rich cells obviously environment, For is are because to protected

as you at look indeed, point that's out. to So interesting point an

XXX tumor, allele a deep, XXX called know, we means variable is because let's technical the in of in is genome choice The the every the for the designing vaccines times. second And crucial the was what frequency. in That times we manner. antigens terms what's personalized sequenced site so is sequenced then say if

precisely XX% material rather the or or XX% XX%. that know tumor given is whether we tumor us person the has or surgeon sample the So biopsy

that a precisely know can are of that answer everything on sample all them. a cells know at present question? whether that And of subset certain tumor in or as tumor Does clonal ones the the is only the far as all present basically rearrangement we in base we your that the in so sample So from material. we are

Operator

Our from Roy next Please with Securities. comes JMP Buchanan proceed. question

Roy Buchanan

should the the Printer us implementing for to about planning first XXXX? think the I RNA questions. How the guess you the we expense German is where with Thanks. printer, government? potentially a development in much finally remind by much Hi. are have GMP taking FDA How The the [ph] and for clinic? financial. is you plans it engage Great. engagement had is using then any in you Can Thanks site the funded trajectory on to of one how the spend ahead trial? on or in X And

Pierre Kemula

down printer don't like you? of now. Hi, take the of closing Pierre. break discussion. the come, cash But year budget a the are per allocation X. Roy. the our when GMP on pass FDA our I'll look to item, How are we It's process questions. I'll probably we or at couple We

a strides position with fee government. we get And doing. subject And the on make the basically right, but GMP pay X, of So the presentation yearly more platform, right. that by through at and of we're we German of resourced, government. have, preparedness, a we to some here all say, year, and sure way government, strengthening is we fully, be changes, to we the then German sell from think have and idea works, to I that would then fuel contract to it's paid The so we it German with So long for but make upfront time, of the and you're following the have we the what should through continue idea right? to this is ready sure pandemic the go I that we client give is would bit in that the same than still able to cash the is the you whole next sense went and year that the the try

Franz-Werner Haas

there you can that printer, -- FDA was question do take this is Ulrike, so the on a maybe, on the Yes, discuss one. with we and

Ulrike Gnad-Vogt

Yes.

several So interactions of and 'XX, printer. FDA, will with we this questions during including to the health related also plan course address the authority interactions

Roy Buchanan

then you're it the Thanks. using great. to they Is LNP? Xs maybe two conducted be like follow IM, a sounds talking where Okay, LNP. Phase are using And about, you cancer delivery? Are The going It up. what's that and you're IV?

Ulrike Gnad-Vogt

be time. will Yes, actually communicated locations in due the countries and

the and LNP, of LNP using for that same current candidates. prophylactic intramuscularly. use we the will will And vaccine we be your our formulation The question about was injected there part are second

Roy Buchanan

Great. Thank you.

Operator

Our next from with Berenberg. question comes Zhiqiang Shu proceed. Please

Zhiqiang Shu

questions. you much. I have Thank very two

to vaccine And additional pipeline color proof crack. you're cancer going the guess I glioblastoma first wonder all a do today, can the rationale we Any going on as tough is on First the cancer of principle be glioblastoma, for know to use first I a you're proof on of it you there provide two why studies online concept. to would great?

Ulrike Gnad-Vogt

Yes.

So that thank you for question.

we very this see of here a So tough needs future. cancer that's a point standard also in the to time where is potential radiation And the is make at indeed, vaccination is vaccines a a see and residual apply time in indication we have of where or still therapy being tumor an patients controlled in and resection to point tumor care for limited. the space the impact clinical an high surgical window completed opportunity but with where unmet

of treatments discovery potential overcome combination in indication synergistic also to new potentially antigens in invest to additional [indiscernible] and will tests elaborated, microenvironment. look apply for We that immunosuppressive with agents and as the also

Franz-Werner Haas

few certainly doing approach top that of this from Perhaps technological say to also be by been mRNA we've over technology even, with view. on advancements multi-epitope the months the a covered point can last

Ulrike Gnad-Vogt

Exactly.

Zhiqiang Shu

you expression mRNA Got protein formulation? from I second non-pegylated your XX, like the it high in that on data released antibody on new Page on question just Does the LNP, at the titers. then humoral activity looks is proprietary LNP based it. And looking your guess neutralizing

Ulrike Gnad-Vogt

You repeat you could were the for a question? minute. Sorry, breaking up there

Zhiqiang Shu

Sure.

of does some data titers that on new antibody XX, think showed expression non-pegylated at new Slide based on the you the is formulation. LNP wonder neutralizing mean showed you mRNA just On I higher Sorry. technology. protein and -- I are the your your three panels, higher looking formulation using

Ulrike Gnad-Vogt

consider And we Exactly, a trend they at a nothing but the this than And is we positive that trend trend. higher. are this more moment, a see.

there you titers. and that tendency neutralizing see slightly because one interferon it's very is comparable. higher is much yes, that But You -- alpha interferon to gamma antibody the a a see nice

Zhiqiang Shu

Do the in more the cancer platform this used to envision franchise? vaccine be on you infectious disease or

Franz-Werner Haas

LNPs therapy. So that's exactly an franchises that this of improvement And exactly molecular we is certainly prophylactic investigating. see have; oncology, the and and vaccines, are the we then what we also the is that's one

oncology be or is saying to exactly even will this in start was we as available these part moment. be even we the optimized the are -- the core. our applied at field going where see bring we to So is But then areas, the of vaccines certainly used. oncology start own technology, a and field, with it's Ulrike then what different before, into LNPs we certainly which LNPs, Certainly, and on though our

Zhiqiang Shu

Great. Thanks very much. Congrats.

Operator

Our comes Kempen Please proceed. Morgado next [ph]. from question Luisa with

Unidentified Analyst

Hi. Thanks have my one. just for taking question. I

For the cancer predict the do be you cancer vaccines? for ratio what shelf personalized or vaccines, the will off

Franz-Werner Haas

mean we developed trials as will see a you in You in that's and we're let's are off under groups And because shelf, -- introduction, the I question? both long-term will applicable course, between both one both. cannot And pointed for which will of full. patient the but that will be that there is development, required be for approaches. Does developing ratio the reach but each enough, and of the your view, by developing out answer in they was they for be those patient think which an be, -- of say, and because one groups space other numbers

Unidentified Analyst

that the in idea any the is and maybe any, of patients what have one of it? other terms you Do need of will Yes. percentage number

Franz-Werner Haas

approach. early an different It's really to entirely say. That's also

go required personalized You in have But to it's scalability because for tell. and that to right, time shelf, and of favorable. fully it's course off then efficacy, needs if keep if is mind, will the one

Unidentified Analyst

Thanks.

Operator

up JMP. We with have proceed. from Roy Buchanan a Please follow

Roy Buchanan

first for read I'm Thanks might sense up. the and a if the just taking great. one flu Appreciate first. in Hi, which out quarter. detailed timing the you of the trials wondering for COVID have follow

Franz-Werner Haas

yet, fully That's that good will say there's on it's elderly, the very close, said, the completed exactly of say. a cannot recruitment, a is you everything question. finalized is here. the But to readout. And And But say, very recruitment. as will events timelines the certain We here. that hope hard a -- in say. it have it's This sequence very come we to if especially to as therefore we not what the decide this on I hard go will hard recruitment because not is will complete then very take

Roy Buchanan

Okay, got Slide I a XX. it. workflow the on And then question on detailed guess

personal other some you that's there in relevant assume the setting grade fill just because out. not that's and have vaccine You or explain Thanks. finish Can reason. is I that?

Franz-Werner Haas

on. workflow asking weeks, the two is You from sample is are we the design Yes, And and then, go the six XX. which within needs controlled. eight about at Slide manufactured what the of vaccine. and their that in we're course, it weeks taken to quality be within that is And max, reasonable there to sample clinical currently in should so be of done to timing working can practice

in exactly a where small everything have should at role got the been the either. same and And you play As you referring scales, to factor spot. the have not then printer and a then is the fill finish that the here this should be limiting finish, fill

Roy Buchanan

it. Okay, you. Thank got

Operator

Thank like to would turn the you. over At comments. back management closing to call this for I time,

Sarah Fakih

conclude this, much call. would conference participation. we Thank you this With for like very to your

CureVac (CVAC) 16 Nov 222022 Q3 Earnings call transcript